ASTRAZENECA : TO LAUNCH DATVERZO IN INDIA

• AstraZeneca Pharma India to launch Datopotamab Deruxtecan (brand name Datverzo) in India in November 2026 • Company had received Import and Market Permission in Form CT-20 from the Drugs Controller General of India, intimated on 17 December 2025 • Datverzo approved for adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer • Indication covers patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease

AstraZeneca Pharma India Ltd

Open attachment

← Back to feed